Open Medicine最新文献

{"title":"Strategies for hyperkalemia management in dialysis patients: A systematic review.","authors":"Anneliese Zevallos-Aquije, Axel Zevallos-Aquije, Rosa Alejandra Salas-Bolaños, Alvaro Maravi-Cardenas, Karen Palomino-Salcedo","doi":"10.1515/med-2025-1301","DOIUrl":"10.1515/med-2025-1301","url":null,"abstract":"<p><strong>Background: </strong>Hyperkalemia is a potentially life-threatening electrolyte disorder, especially in patients with chronic kidney disease and those undergoing dialysis. Its management is complex due to the need to balance potassium control with overall patient stability.</p><p><strong>Objectives: </strong>The aim of this systematic review is to evaluate current therapeutic strategies for hyperkalemia in dialysis patients, including diuretics, ion-exchange resins, and newer agents such as sodium zirconium cyclosilicate (SZC).</p><p><strong>Methods: </strong>A systematic search was conducted in Scopus and Web of Science, applying filters for language, recency (≤5 years), and journal quality. After removing duplicates and irrelevant records, 11 high-quality studies were included.</p><p><strong>Results: </strong>New therapies like SZC and patiromer demonstrated efficacy in maintaining safe potassium levels. The potassium binding pack showed promise in acute and resource-limited settings. Evidence challenges strict dietary potassium restrictions, especially regarding plant-based foods, and highlights the importance of individualized nutritional plans. Continuous potassium monitoring is essential to preserve residual kidney function.</p><p><strong>Conclusion: </strong>Hyperkalemia management in dialysis patients benefits from an integrated approach combining pharmacologic treatment, tailored nutrition, and close monitoring. Novel interventions and evolving dietary guidelines may improve safety, effectiveness, and quality of life in this vulnerable population.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20251301"},"PeriodicalIF":1.6,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12596852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145489842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OKAIN: A comprehensive oncology knowledge base for the interpretation of clinically actionable alterations.","authors":"Zhenhua Yang, Chunwei Xu, Mingmin Wang, Xinxiu Meng, Kai Wang, Aodi Wang","doi":"10.1515/med-2025-1289","DOIUrl":"10.1515/med-2025-1289","url":null,"abstract":"<p><p>The increased use of next-generation sequencing in clinical genetic testing has resulted in the identification of several genetic variations with possible therapeutic implications. We developed OKAIN (https://szcube.origimed.com), an algorithm tool that assesses clinically actionable mutations using a precision oncology knowledge database. OKAIN employs a weighted evidence analysis system to deliver final clinical annotation outcomes for intricate variations. As of now, OKAIN has amassed over 100,000 variants in 1,239 cancer-associated genes, encompassing 12,409 entries of therapeutic evidence in 471 genes. This collection highlights 2,600 Level A evidence entries in 66 genes, with 864 entries derived from the National Medical Products Administration labels or Chinese guidelines. OKAIN acts as a precision oncology knowledge base for the assessment of clinically actionable alterations, integrating exhaustive data related to cancer-associated genomic variants and therapeutic efficacy. Analyzing patient variants with OKAIN reveals more actionable targeted therapy or immunotherapy options, potentially improving treatment outcomes.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20251289"},"PeriodicalIF":1.6,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12596872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145489859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The current status and influence factors of research ability among community nurses: A sequential qualitative-quantitative study.","authors":"Yi Qin, Li Yan, Ying Zhang, Jordan Tovera Salvador, Linlin Liu","doi":"10.1515/med-2025-1314","DOIUrl":"10.1515/med-2025-1314","url":null,"abstract":"<p><strong>Background and aim: </strong>The study used a sequential qualitative-quantitative research design to develop a survey tool that explores the current situation and influencing factors of community nurses' research ability.</p><p><strong>Methods: </strong>The qualitative research developed the Chinese Community Nurses Research Ability Tool (CCN-RAT) through face-to-face interviews. The quantitative research tests the current situation and influencing factors of research ability among community nurses. One-way ANOVA and Multiple Linear Regression were used to analyze the results.</p><p><strong>Results: </strong>The Cronbach's <i>α</i> was found to be 0.993, and the Subject-Content Validity Index was 0.99 using CCN-RAT. Most of the community nurses had a low to moderate level of research ability. Age (95%CI: 1.812-9.533, <i>P</i> = 0.004), educational attainment (95%CI: 4.667-11.660, <i>P</i> < 0.001), working experience year (95%CI: 0.274-1.0410, <i>P =</i> 0.001), number of participants in research projects (95%CI: 0.239-11.130, <i>P</i> = 0.041), number of published articles in Chinese core journal or SCI (95%CI: 19.354-36.969, <i>P</i> < 0.001), and number of participants in research training (95%CI: 18.289-28.218, <i>P</i> < 0.001) were significant influencing factors on research ability among community nurses.</p><p><strong>Conclusion: </strong>CCN-RAT could help nurses, educators, students, and other populations to better understand the current situation and influencing factors of research ability, which could provide targeted research training to improve research ability for public health staff.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20251314"},"PeriodicalIF":1.6,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12596853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145489917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton pump inhibitors-induced thrombocytopenia: A systematic literature analysis of case reports.","authors":"Xiaofei Yue, Hongjiao Tian","doi":"10.1515/med-2025-1297","DOIUrl":"10.1515/med-2025-1297","url":null,"abstract":"<p><strong>Objective: </strong>Thrombocytopenia induced by proton pump inhibitors (PPIs) is a relatively uncommon adverse effect of this widely prescribed class of drugs. The objective of this study is to investigate the clinical features of PPIs-induced thrombocytopenia based on published case reports.</p><p><strong>Methods: </strong>We searched the PubMed, Web of Science, Scopus, China National Knowledge Infrastructure, Wanfang Data, and Chinese VIP databases from inception to August 2024 to identify reported cases of thrombocytopenia associated with PPIs use. Clinical data such as patient demographics, drug use information, adverse reactions, and outcomes were extracted and analyzed.</p><p><strong>Results: </strong>Overall, 16 publications describing 18 cases (12 males and 6 females) were included in this study, comprising a neonate and 17 adults with a median age of 62 years (range 23-98). The PPIs associated with thrombocytopenia included pantoprazole (11 cases), lansoprazole (4 cases), omeprazole (2 cases), and esomeprazole (1 case). The median time to symptoms onset was 3 days (range 2-7) after the initiation of PPI therapy. After discontinuation of PPIs and interventions such as platelet transfusion, 11 patients achieved recovery, and the remaining 7 patients experienced symptomatic improvement.</p><p><strong>Conclusion: </strong>Thrombocytopenia induced by PPIs appears to be a rare adverse event. Clinicians should enhance their awareness when evaluating potential cases of thrombocytopenia. Once PPIs are suspected, immediate discontinuation of the drugs and initiation of appropriate treatments are recommended.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20251297"},"PeriodicalIF":1.6,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12596856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145489926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective role of selenium in sepsis: Mechanisms and potential therapeutic strategies.","authors":"Yukun Liu, Xuan Zhao, Zhikai Xu, Zhanfei Li, Yuchang Wang","doi":"10.1515/med-2025-1296","DOIUrl":"10.1515/med-2025-1296","url":null,"abstract":"<p><p>Sepsis is an inflammatory disease caused by a severe infection, and its pathological process involves complex immune reactions and inflammatory cascades. This condition often leads to multiple organ dysfunction syndrome, which is one of the main causes of patient mortality. In recent years, researchers have paid extensive attention to the protective role of selenium (Se) in sepsis. Se is believed to potentially counteract organ dysfunction caused by sepsis through various mechanisms and is considered a potential therapeutic strategy. This review extensively discusses the potential mechanisms of Se in sepsis. We explore the antioxidant and anti-inflammatory properties of Se, as well as its regulatory effects on immune cell activity, expression of inflammatory mediators, and oxidative stress. In addition, we examine the impact of Se on organ damage and organ dysfunction caused by sepsis, with a focus on its protective effects on important organs such as the cardiovascular system, respiratory system, kidneys, and liver. We evaluate relevant preclinical and clinical studies to assess the potential of Se as a treatment for sepsis-related organ dysfunction. We discuss the optimization of Se administration routes, dosages, and timing, and summarize the impact of Se on clinical outcomes and survival rates. In summary, Se demonstrates significant potential as a therapeutic strategy in sepsis-related organ dysfunction. However, further research is still needed to delve into the mechanisms of Se and optimize its application in clinical practice. This will provide breakthroughs in the treatment of sepsis patients, improving their prognosis and survival rates.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20251296"},"PeriodicalIF":1.6,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12596874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145489911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CSF2 polarized neutrophils and invaded renal cancer cells <i>in vitro</i> influence.","authors":"Yuan Song, Husong Su, Yu Fan, Junfeng Huang, Sheng Xue","doi":"10.1515/med-2025-1239","DOIUrl":"10.1515/med-2025-1239","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the role and underlying mechanisms of colony-stimulating factor 2 (CSF2) in the progression of kidney renal clear cell carcinoma (KIRC).</p><p><strong>Methods: </strong>Transcriptomic and clinical data from The Cancer Genome Atlas were analyzed to assess the correlation between CSF2 expression, clinicopathological features, and patient prognosis. A neutrophil-tumor co-culture system was established to examine the effects of CSF2 on neutrophil polarization, tumor cell proliferation, migration, apoptosis, and autophagy. Protein expression was evaluated by flow cytometry, Western blot, and immunofluorescence. PD-L1 knockout and autophagy inhibitors (3-methyladenine and chloroquine) were used to explore regulatory mechanisms.</p><p><strong>Results: </strong>CSF2 expression was significantly upregulated in KIRC tissues and was positively associated with advanced tumor stage and poor prognosis. <i>In vitro</i>, CSF2 promoted neutrophil polarization toward the tumor-supportive N2 phenotype and enhanced the proliferation and migration of renal cancer cells while inhibiting apoptosis and reactive oxygen species production. Additionally, CSF2 upregulated PD-L1 expression in tumor cells and activated autophagy by increasing LC-3, Beclin1, and ATG7 levels. These effects were reversed by PD-L1 knockout or treatment with the autophagy inhibitor 3-methyladenine.</p><p><strong>Conclusion: </strong>CSF2 promotes KIRC progression through PD-L1-mediated neutrophil polarization and autophagy activation, representing a potential therapeutic target.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20251239"},"PeriodicalIF":1.6,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12596868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145489867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between the expression of copper death promoting factor SLC31A1 in papillary thyroid carcinoma and clinicopathological indicators and prognosis.","authors":"Chenkun He, Rongrong Liu, Tianli Zhou","doi":"10.1515/med-2025-1220","DOIUrl":"10.1515/med-2025-1220","url":null,"abstract":"<p><strong>Objective: </strong>This study investigates the association between serum SLC31A1, a copper death-promoting factor, and clinicopathological features/prognosis in papillary thyroid carcinoma (PTC).</p><p><strong>Methods: </strong>A cohort of 250 PTC patients was stratified into good (<i>n</i> = 205) and poor (<i>n</i> = 45) prognosis groups. Clinicopathological parameters (age, sex, tumor diameter, differentiation, TNM stage, thyroid exocapsular invasion, lymph node metastasis) and serum SLC31A1 levels (measured via ELISA) were analyzed. Patients were further categorized into high/low SLC31A1 expression groups based on median values. Prognostic correlations were evaluated using Kaplan-Meier survival analysis, Cox regression, and receiver operating characteristic (ROC) curve assessment.</p><p><strong>Results: </strong>Elevated serum SLC31A1 levels were significantly associated with poor prognosis, advanced TNM stages (III/IV), poor differentiation, thyroid exocapsular invasion, and lymph node metastasis. Multivariate Cox analysis identified high SLC31A1 as an independent predictor of poor prognosis (HR = 1.235, 95% CI 1.158-1.317). ROC analysis demonstrated strong predictive accuracy for SLC31A1 in prognosis assessment (AUC = 0.859).</p><p><strong>Conclusion: </strong>High serum SLC31A1 expression correlates with aggressive clinicopathological features and independently predicts adverse outcomes in PTC patients, suggesting its potential as a prognostic biomarker for clinical stratification.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20251220"},"PeriodicalIF":1.6,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12596857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145489832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Motivational interviewing for alcohol use reduction in Thai patients.","authors":"Rattikorn Muangnang, Mullika Singhasuriya, Amâncio António de Sousa Carvalho","doi":"10.1515/med-2025-1307","DOIUrl":"10.1515/med-2025-1307","url":null,"abstract":"<p><strong>Background and aim: </strong>Alcohol consumption is a major public health issue, linked to a wide range of physical, psychological, familial, and social harms, as well as increased rates of violence, accidents, and mortality. The aim of this study is to evaluate the effectiveness of a motivational interviewing program in reducing alcohol consumption patterns among Thai patients.</p><p><strong>Methods: </strong>This quasi-experimental study included a control group (CG) and an experimental group (EG), each consisting of 30 patients. Data were collected using a structured questionnaire and analyzed with SPSS, utilizing both descriptive and inferential statistical methods.</p><p><strong>Results: </strong>The majority of patients in the CG were aged 45-60 years, whereas the majority in the EG were aged 25-44 years. The intervention involved 4 sessions over 8 weeks motivational interviewing program (MIP). The mean AUDIT scores in the CG were 24.10 before the intervention and 22.90 after, while in the EG, scores decreased from 22.63 to 19.33. The interaction between the factors (CG and EG) before the intervention did not have a significant effect (Multivariate Analysis of Variance, MANOVA: <i>p</i> = 0.255), but was significant after the intervention (MANOVA: <i>p</i> = 0.009).</p><p><strong>Conclusion: </strong>MIP had a significant effect on reducing alcohol consumption among patients of the EG.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20251307"},"PeriodicalIF":1.6,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12596865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145489916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Luteolin alleviates oxygen-glucose deprivation/reoxygenation-induced neuron injury by regulating NLRP3/IL-1β signaling.","authors":"Fei Yu, Guangxue Wang, Xingyi Chen, Yanfei Zhang, Cheng Yang, Hui Hu, Liang Wei","doi":"10.1515/med-2025-1198","DOIUrl":"10.1515/med-2025-1198","url":null,"abstract":"<p><p>We aimed to investigate the protective effect of luteolin against neuron injury induced by oxygen-glucose deprivation/reoxygenation (OGD/R), and to further elucidate the roles of NLRP3 in luteolin-mediated regulation of neuron injury. Using Schwann (SW) 10 cells, an OGD/R-induced neuron injury model was established, and six experimental groups were designated. Subsequently, cell viability and apoptosis were respectively detected by cell counting kit 8 and flow cytometry. Reactive oxygen species (ROS) levels were measured via flow cytometry with a ROS assay kit. Moreover, the expression of interleukin (IL)-6, IL-1β, NLRP3, and MMP9 was examined by real-time quantitative PCR and Western blot. Compared with control cells, OGD/R significantly reduced cell viability and increased apoptosis, ROS levels, and the mRNA levels of <i>IL-6</i>, <i>IL-1β</i>, <i>NLRP3</i>, and <i>MMP9</i>. Luteolin significantly enhanced OGD/R-induced cell viability and alleviated apoptosis in SW10 cells (<i>P</i> < 0.05). Additionally, luteolin suppressed ROS levels, along with the expression of IL-1β, IL-6, NLRP3, and MMP9 induced by OGD/R. Furthermore, BMS-986299 significantly decreased the cell viability and increased the expression of inflammatory factors in OGD/R-induced SW10 cells treated with luteolin. This inhibitory effect was reversed by NLRP3 knockdown. In conclusion, luteolin may exert a protective effect on OGD/R-induced nerve injury by inhibiting the NLRP3/IL-1β signaling pathway.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20251198"},"PeriodicalIF":1.6,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12619634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145541881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polyphyllin II inhibits thyroid cancer cell growth by simultaneously inhibiting glycolysis and oxidative phosphorylation.","authors":"Jianwei Sun, Ding Ding, Qian Xiang, Mengyang Zheng, Mingming Dai","doi":"10.1515/med-2025-1286","DOIUrl":"10.1515/med-2025-1286","url":null,"abstract":"<p><strong>Background: </strong>Thyroid cancer is the most common malignancy of the endocrine system, and effective treatments for metastatic disease are still lacking. Targeting both glycolysis and oxidative phosphorylation (OXPHOS) simultaneously represents a novel approach to cancer therapy. While polyphyllin has been shown to modulate cellular metabolism in various cancers, its role in thyroid cancer remains unexplored.</p><p><strong>Purpose: </strong>This study aimed to explore the antitumor effects and underlying mechanisms of polyphyllin in thyroid cancer.</p><p><strong>Methods: </strong>Thyroid cancer cells were treated with varying concentrations of Polyphyllin I, II, VI, and VII. Cell viability was assessed using the CCK-8 assay to identify the most effective polyphyllin compound and its optimal dosage. Colony formation and EdU incorporation assay were performed to evaluate cell proliferation, while Transwell assays were used to assess cell invasion. Cell migration ability was examined using the wound healing assay. The effect of Polyphyllin II on OXPHOS was evaluated using an extracellular oxygen consumption rate (OCR) assay kit. Glucose uptake, lactate production, glycolysis-related protein expression, and the extracellular acidification rate (ECAR) were measured to assess the effects of Polyphyllin II on glycolysis in thyroid cancer cells. Flow cytometry and western blotting were conducted to detect apoptosis.</p><p><strong>Results: </strong>Polyphyllin I, II, VI, and VII all inhibit the proliferation of thyroid cancer cells, with Polyphyllin II showing the most potent inhibitory effect. Polyphyllin II suppresses cell proliferation, invasion, and migration of thyroid cancer cells, while also promoting apoptosis. Mechanism studies reveal that Polyphyllin II inhibits extracellular OCR, basal respiration, maximum respiration, ATP-linked respiration, spare respiration capacity, glucose uptake, lactate production, glycolytic rate-limiting enzymes, and the ECAR in thyroid cancer cells.</p><p><strong>Conclusion: </strong>Polyphyllin II simultaneously inhibits glycolysis and OXPHOS, thereby suppressing the invasion, migration, and proliferation of thyroid cancer cells, while also promoting apoptosis.</p>","PeriodicalId":19715,"journal":{"name":"Open Medicine","volume":"20 1","pages":"20251286"},"PeriodicalIF":1.6,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12596855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145489839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}